These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8478666)

  • 21. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250.
    Uemura H; Okajima E; Debruyne FM; Oosterwijk E
    Int J Cancer; 1994 Feb; 56(4):609-14. PubMed ID: 7509324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
    Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
    Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
    Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
    Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
    van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
    Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.
    Sands H; Jones PL; Shah SA; Palme D; Vessella RL; Gallagher BM
    Cancer Res; 1988 Jan; 48(1):188-93. PubMed ID: 3334993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.
    Uemura H; Nakagawa Y; Yoshida K; Saga S; Yoshikawa K; Hirao Y; Oosterwijk E
    Br J Cancer; 1999 Oct; 81(4):741-6. PubMed ID: 10574265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer.
    Finstad CL; Lloyd KO; Federici MG; Divgi C; Venkatraman E; Barakat RR; Finn RD; Larson SM; Hoskins WJ; Humm JL
    Clin Cancer Res; 1997 Aug; 3(8):1433-42. PubMed ID: 9815829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-G250 nanobody-functionalized nanobubbles targeting renal cell carcinoma cells for ultrasound molecular imaging.
    Yu Z; Hu M; Li Z; Dan Xu ; Zhu L; Guo Y; Liu Q; Lan W; Jiang J; Wang L
    Nanotechnology; 2020 May; 31(20):205101. PubMed ID: 32107342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.
    Oosterwijk-Wakka JC; Boerman OC; Mulders PF; Oosterwijk E
    Int J Mol Sci; 2013 May; 14(6):11402-23. PubMed ID: 23759990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibody.
    Wang G; Wu Z; Wang Y; Li X; Zhang G; Hou J
    Oncotarget; 2016 Apr; 7(17):24888-98. PubMed ID: 27058890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
    Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas.
    Steffens MG; Oosterwijk E; Zegwaart-Hagemeier NE; van't Hof MA; Debruyne FM; Corstens FH; Boerman OC
    Br J Cancer; 1998 Nov; 78(9):1208-13. PubMed ID: 9820182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.